Bajaj Healthcare FY26: Revenue Up 12%, Profit Falls Amid Middle East Reversal

Bajaj Healthcare reported its audited financial results for the fiscal year ending March 31, 2026. The company saw revenues increase by 12% to ₹611.03 crore, but its Profit Before Tax (PBT) declined significantly.

Financial Performance

For FY26, Bajaj Healthcare posted revenue from operations of ₹611.03 crore, up from ₹542.60 crore in the previous fiscal year. Despite this revenue growth, Profit Before Tax (PBT) dropped by approximately 37% to ₹28.92 crore, compared to ₹46.01 crore in FY25. Total Comprehensive Income also fell to ₹16.38 crore from ₹40.87 crore in the prior year.

The Board of Directors has recommended a final dividend of 30%, which amounts to ₹1.50 per equity share of ₹5 face value, pending shareholder approval at the upcoming Annual General Meeting.

Profitability Challenges

The notable decline in profitability was largely due to a ₹33.24 crore reversal of income. This reversal stems from ongoing regional instability in the Middle East, which has affected a customer's ability to meet commitments related to a technical know-how arrangement. While the dividend offers a direct return to shareholders, the profit dip highlights external pressures impacting the company's bottom line.

Company Overview and Acquisition Plan

Bajaj Healthcare is a pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms. The company's revenue for FY25 was ₹542.60 crore with a PBT of ₹46.01 crore. A significant ongoing development is the proposed acquisition of Genrx Pharmaceuticals Private Limited, which is currently awaiting necessary approvals from the National Company Law Tribunal (NCLT).

Corporate Governance Updates

The company appointed JCR & Co. LLP as its new Internal Auditors. Additionally, V.J. Talati & Co. has been re-appointed as Cost Auditors for FY27. These appointments ensure continued financial oversight for the upcoming fiscal periods.

Key Risks

The primary risk remains the impact of regional instability in the Middle East on contractual obligations and revenue recognition, as demonstrated by the recent income reversal. Uncertainty surrounding the timeline and outcome of the NCLT approval process for the Genrx Pharmaceuticals acquisition also poses a potential challenge to future business consolidation and performance.

Industry Context

For broader industry comparison, peers like Aarti Drugs Ltd, which manufactures APIs and intermediates, reported FY23 revenues of ₹760 crore and a PAT of ₹35 crore. Venus Remedies Ltd, another pharmaceutical entity, posted FY23 revenues of ₹244 crore and a net loss of ₹17 crore. These figures provide a general market perspective.

Investor Watchlist

Key developments for shareholders to monitor include:

• Shareholder approval at the upcoming Annual General Meeting for the recommended final dividend.
• Updates on the National Company Law Tribunal (NCLT) approval status for the Genrx Pharmaceuticals acquisition.
• Any further developments or resolutions regarding the Middle East customer's commitments and associated revenue recognition.
• The company's strategy for mitigating the impact of geopolitical instability on its international business segments.